您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > WSF1-IN-1
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
WSF1-IN-1
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
WSF1-IN-1图片
规格:98%
分子量:446.43
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
WSF1-IN-1 (compound 136) 是具有口服活性的 WSF1 抑制剂,可用于Wolfram 综合征基因 WSF1 相关的肿瘤研究,其在HepG2 母源细胞系和 HepG2 WFS1 KO 细胞系中的 IC50 值分别为 0.33 μM 和>27 μM。
货号:ajcx33798
CAS:2379577-82-7
分子式:C20H21F3N8O
分子量:446.43
溶解度:DMSO : 100 mg/mL (224.00 mM; Need ultrasonic)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC50 values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively[1].

WSF1-IN-1 (compound 136) exhibits IC50 values of >27 μM and 0.03 μM for Hek293 empty vector and Hek293 WFS1 over-expressor, respectively. WSF1-IN-1 (compound 136) exhibits IC50 values of 0.05 μM (Colo-205 Control shRNA), >9 μM (Colo-205 WSF1 shRNA), 0.08 μM (DU4415 Control shRNA), 6.1 μM (DU4415 WSF1 shRNA), 0.26 μM (HepG2 Control shRNA), 2.2 μM (HepG2 WSF1 shRNA) for cell valiablity, respectively[1].

WSF1-IN-1 (compound 136, 100 mpk qd, orally, 14 days) exhibits 106.65% tumor growth inhibition (TGI) in NSCLC patient derived xenograft OD33996 nu/nu mice[1].

[1]. Lauffer, David J, et al. Preparation of pyridine compass. for the treatment of cellular proliferative disorders. US 20190322673 A1.